scispace - formally typeset
T

Thomas J. Dengler

Researcher at Heidelberg University

Publications -  165
Citations -  7590

Thomas J. Dengler is an academic researcher from Heidelberg University. The author has contributed to research in topics: Transplantation & Heart transplantation. The author has an hindex of 43, co-authored 164 publications receiving 6924 citations. Previous affiliations of Thomas J. Dengler include Yale University & University Hospital Heidelberg.

Papers
More filters
Journal ArticleDOI

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients

Maria Rosa Costanzo, +56 more
TL;DR: Institutional Affiliations Chair Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA Task Force 1 Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland Clinic Foundation, Cleveland, Ohio, USA; Starlings R: University of Chicago, Chicago, Illinois,USA; Chan M: university of Alberta, Edmonton, Alberta, Canada ; Desai S: Inova Fairfax Hospital, Fairfax, Virginia, USA.
Journal Article

Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.

TL;DR: It is shown that Ang-1 dose-dependently stabilizes HUVEC network organization for up to 48 hours and interacts with other angiogenic molecules to stabilize vascular structures by promoting the survival of differentiated ECs.
Journal ArticleDOI

Inhibition of IL-17A Attenuates Atherosclerotic Lesion Development in ApoE-Deficient Mice

TL;DR: The present data support a pathogenic role of IL-17A in the development of atherosclerosis by way of its widespread proinflammatory and proapoptotic effects on atherogenic cells.
Journal ArticleDOI

Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

TL;DR: Better predictors of arrhythmia-associated SCD and randomized trials are required to elucidate the impact of ICD placement in high-risk patients with cardiac amyloidosis.
Journal ArticleDOI

Poly(ADP-Ribose) Polymerase Inhibition Reduces Reperfusion Injury After Heart Transplantation

TL;DR: Pharmacological PARP inhibition reduces reperfusion injury after heart transplantation due to prevention of energy depletion and downregulation of adhesion molecules and exerts a beneficial effect against reperfusions-induced graft coronary endothelial dysfunction.